2022
Randomized trial of diet and exercise on chemotherapy completion in women with breast cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) study.
Sanft T, Harrigan M, Cartmel B, Li F, Zupa M, McGowan C, Ferrucci L, Puklin L, Nguyen T, Tanasijevic A, Neuhouser M, Hershman D, Basen-Engquist K, Jones B, Knobf M, Chagpar A, Silber A, Ligibel J, Irwin M. Randomized trial of diet and exercise on chemotherapy completion in women with breast cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) study. Journal Of Clinical Oncology 2022, 40: 12007-12007. DOI: 10.1200/jco.2022.40.16_suppl.12007.Peer-Reviewed Original ResearchRelative dose intensityHigh relative dose intensityBreast cancerDose-response effectPhysical activityPA interventionsNeoadjuvant chemotherapyChemotherapy completionDiet qualityStage I breast cancerEndocrine therapy adherenceTrial of dietDifferent chemotherapy regimensI breast cancerBody mass indexPatient-reported outcomesHealthy Eating IndexBetter diet qualityHigh physical activityMore physical activityElectronic medical recordsChi-square testUC participantsChemotherapy regimensSecondary endpoints
2020
Abstract P6-02-01: The effect of background parenchymal enhancement on the predictive performance of functional tumor volume measured in MRI
Li W, Onishi N, Newitt D, Harnish R, Jones E, Wilmes L, Gibbs J, Price E, Joe B, Chien A, Berry D, Boughey J, Albain K, Clark A, Edmiston K, Elias A, Ellis E, Euhus D, Han H, Isaacs C, Khan Q, Lang J, Lu J, Meisel J, Mitri Z, Nanda R, Northfelt D, Sanft T, Stringer-Reasor E, Viscusi R, Wallace A, Yee D, Yung R, Melisko M, Perlmutter J, Rugo H, Schwab R, Symmans W, van't Veer L, Yau C, Asare S, DeMichele A, Goudreau S, Abe H, Sheth D, Wolverton D, Fountain K, Ha R, Wynn R, Crane E, Dillis C, Kuritza T, Morley K, Nelson M, Church A, Niell B, Drukteinis J, Oh K, Jafarian N, Brandt K, Choudhery S, Bang D, Mullins C, Woodard S, Zamora K, Ojeda-Fornier H, Eghedari M, Sheth P, Hovanessian-Larsen L, Rosen M, McDonald E, Spektor M, Giurescu M, Newell M, Cohen M, Berman E, Lehman C, Smith W, Fitzpatrick K, Borders M, Yang W, Dogan B, Esserman L, Hylton N. Abstract P6-02-01: The effect of background parenchymal enhancement on the predictive performance of functional tumor volume measured in MRI. Cancer Research 2020, 80: p6-02-01-p6-02-01. DOI: 10.1158/1538-7445.sabcs19-p6-02-01.Peer-Reviewed Original ResearchEffect of background parenchymal enhancementFunctional tumor volumeBackground parenchymal enhancementLower background parenchymal enhancementNeoadjuvant chemotherapyTumor volumeParenchymal enhancementDynamic contrast-enhancedHR-/HER2Treatment time pointsContralateral breastPatient cohortTime pointsHigher background parenchymal enhancementI-SPY 2 TRIALWeeks of neoadjuvant chemotherapyLocally advanced breast cancerMRI examsHormone receptorsHR-/HER2- subtypeMR tumor volumesPrediction of pCRNeoadjuvant chemotherapy regimensEnhancement thresholdHR-/HER2+Abstract PD9-05: Lack of background parenchymal enhancement suppression in breast MRI during neoadjuvant chemotherapy may be associated with inferior treatment response in hormone receptor positive breast cancer
Onishi N, Li W, Newitt D, Harnish R, Gibbs J, Jones E, Nguyen A, Wilmes L, Joe B, Campbell M, Basu A, van’t Veer L, DiMichele A, Yee D, Berry D, Albain K, Boughey J, Chien A, Clark A, Edmiston K, Elias A, Ellis E, Euhus D, Han H, Isaacs C, Khan Q, Lang J, Lu J, Meisel J, Mitri Z, Nanda R, Northfelt D, Sanft T, Stringer-Reasor E, Viscusi R, Wallace A, Yung R, Melisko M, Perlmutter J, Rugo H, Schwab R, Symmans W, Asare S, Yau J, Yau C, Esserman L, Hylton N. Abstract PD9-05: Lack of background parenchymal enhancement suppression in breast MRI during neoadjuvant chemotherapy may be associated with inferior treatment response in hormone receptor positive breast cancer. Cancer Research 2020, 80: pd9-05-pd9-05. DOI: 10.1158/1538-7445.sabcs19-pd9-05.Peer-Reviewed Original ResearchPathological complete responseBackground parenchymal enhancementInferior treatment responseHormone receptor-positive breast cancerPathologic complete response rateReceptor-positive breast cancerPositive breast cancerTreatment responseHR cohortBreast cancerBreast MRINeoadjuvant chemotherapyNon-pCRDegree of BPEI-SPY 2 TRIALQuantitative background parenchymal enhancementStage II/III breast cancerContralateral breast parenchymaPost-NAC MRIHormone receptor statusHR+ breast cancerEffects of chemotherapyEnhanced suppressionStatistically significant associationHR+ cancers